A large US government order for a corona vaccine has breathed life into BioNTech shares. The value of the vaccine on the Nasdaq technology exchange rose by five percent on Thursday. Goldman Sachs analysts then reacted and raised their estimates for the Mainz-based biotech company.
American investment bank Goldman Sachs raised the target price for BioNTech from 206 to 209 US dollars and left the rating at “neutral”. In a study available Thursday, analyst Chris Shibutani adjusted his estimates and price target in light of the United States’ recent order for further quantities of the corona vaccine. The order is positive and will bring additional sales in the second half of the year.
On average, they go to a news agency Bloomberg The aforementioned analysts assume that BioNTech will record a drop in sales from 22.4 to 17.5 billion dollars this year. Adjusted earnings per share are also expected to fall from $46.87 to $36.73. The price/earnings ratio is still attractive 4.
BioNTech will continue to turn a profit this year. Current funds can be used for further development of a wide spectrum, with the oncology research area in particular having great potential in the long term. DER AKTIONÄR remains bullish on the stake and continues to recommend buying it.
(with material from dpa-AFX)
Conflict of interest notice:
CEO and majority owner of the publisher Börsenmedien AG, Mr. Bernd Förtsch, has taken direct and indirect positions on the following financial instruments mentioned in the publication or related derivatives that may benefit from any price development arising from the publication: BioNTech.
BioNTech shares are in the SHAREHOLDER’s depository.